CYP19A1 and gastric adenocarcinoma: Further, higher aromatase mRNA expression led to significantly poorer OS in liver hepatocellular carcinoma (Fig 1E, Table 1) and stomach adenocarcinoma (Fig 1F, Table 1) patients.